Artificial intelligence is beginning to change one of the most difficult areas of healthcare: discovering new medicines.
For several years, AI in drug discovery was primarily associated with predicting protein structures, screening chemical libraries, and identifying patterns in biological datasets. The field is now moving into a more advanced phase. New systems are being designed not only to predict biological structures, but also to reason across proteins, DNA, RNA, antibodies, chemical compounds, and experimental results.
This shift is creating a new model of pharmaceutical research known as lab-in-the-loop drug discovery. In this approach, an AI system proposes promising molecules, physical experiments test those candidates, and the resulting laboratory data is returned to the model for further refinement.
The goal is not to replace scientists. It is to help researchers examine a much larger biological search space and decide which experiments are most valuable.
Why AI Drug Discovery Is Receiving So Much Attention
Traditional drug discovery is a long, uncertain, and expensive process. Researchers must identify a disease-related biological target, find molecules that interact with it, evaluate toxicity, optimise the molecule, and complete several stages of laboratory and clinical testing.
AI can support the early stages of this process by:
- Analysing large biological and chemical datasets
- Predicting protein and molecular interactions
- Identifying potential therapeutic targets
- Generating candidate molecular structures
- Estimating binding affinity and toxicity
- Prioritising compounds for laboratory testing
- Finding new uses for existing or previously unsuccessful drugs
The most important benefit is not that AI can prove a medicine works. Its value is that it can help researchers narrow enormous numbers of possibilities into a smaller set of candidates worth testing.
The Major Change: AI Is Moving Beyond Structure Prediction
Protein structure prediction was a major breakthrough because the three-dimensional shape of a protein strongly influences its biological function.
However, identifying a protein's shape is only one part of drug discovery. Researchers must also understand how that protein interacts with other proteins, nucleic acids, small molecules, antibodies, cells, and biological pathways.
New biological foundation models are therefore being developed to model multiple molecular components together.
This represents a transition from predicting isolated structures toward analysing larger biological systems and interactions.
What Is a Biological Foundation Model?
A biological foundation model is an AI system trained on large collections of biological information.
Depending on the model, its training data may include:
- Protein sequences and structures
- DNA and RNA sequences
- Molecular interaction records
- Chemical compound structures
- Genomic and proteomic datasets
- Scientific publications
- Disease-gene relationships
- Experimental assay results
The model learns statistical and structural patterns connecting biological sequence, structure, and function.
A conventional AI model might be developed for one narrow task, such as predicting whether a molecule will bind to a particular protein. A biological foundation model may support several related tasks and transfer information learned from one biological problem to another.
This does not mean that the model fully understands human biology. It means the model can detect complex relationships that would be difficult for researchers to examine manually.
How Lab-in-the-Loop Drug Discovery Works
A lab-in-the-loop workflow connects computational prediction with physical experimentation.
1. Define the Biological Problem
Researchers identify a disease mechanism, protein, genetic pathway, or cellular process that may represent a therapeutic target.
2. Generate or Screen Candidate Molecules
AI models search existing molecular libraries or generate new structures that may interact with the target.
3. Rank the Candidates
Candidates may be ranked using predicted characteristics such as:
- Binding strength
- Selectivity
- Stability
- Solubility
- Toxicity risk
- Manufacturability
4. Test Selected Candidates
The most promising molecules are sent for laboratory testing. Researchers measure whether the predicted interaction occurs under real experimental conditions.
5. Return Experimental Data to the Model
Laboratory results are used to improve candidate selection. Molecules that fail provide valuable negative data, while successful candidates help the system identify more productive regions of the molecular search space.
6. Repeat the Cycle
The prediction-testing-learning cycle continues until researchers identify candidates suitable for more extensive preclinical evaluation.
The Growing Role of Multi-Omics AI
A disease is rarely controlled by a single gene or protein. Biological conditions emerge from interactions across multiple levels of the body.
Multi-omics research combines several types of biological information, including:
- Genomics: DNA sequence and genetic variation
- Transcriptomics: RNA expression
- Proteomics: Protein abundance and activity
- Metabolomics: Small molecules produced by cellular processes
- Epigenomics: Chemical regulation of gene activity
AI can help integrate these datasets and identify relationships that may not be visible when each dataset is analysed separately.
Multi-omics AI could help researchers move from asking:
Does this molecule bind to this protein?
to a more clinically meaningful question:
How might this intervention influence the wider biological system in different groups of patients?
Drug Repurposing Is Another Important Opportunity
AI drug discovery is not limited to creating completely new molecules.
Models can analyse existing medicines and previously unsuccessful drug candidates to identify alternative diseases or biological pathways where they may be useful. This is known as drug repurposing.
A drug may have failed because it was tested for the wrong condition, administered to an unsuitable patient population, or evaluated before researchers understood the relevant biological mechanism.
By combining chemical information, gene expression, disease pathways, and clinical evidence, AI may help researchers identify new hypotheses for these compounds.
These computational results are hypotheses rather than clinical conclusions. Any proposed new use must still undergo appropriate experimental, safety, and regulatory evaluation.
What AI Still Cannot Replace
Despite rapid progress, AI cannot eliminate the fundamental requirements of biomedical research.
An AI-generated molecule is not automatically a medicine. It remains a computational candidate until researchers establish that it can be manufactured, delivered safely, and shown to produce the intended biological effect.
AI models may also be affected by:
- Incomplete or low-quality training data
- Experimental inconsistencies
- Dataset bias
- Limited biological context
- Incorrect molecular assumptions
- Poor reproducibility
- Insufficient interpretability
- Overconfident predictions
Human biology also contains interactions that may not be represented in current datasets. A molecule that performs well in a computer simulation may fail in cells, animal models, or human trials.
For this reason, AI tools should be used to prioritise research rather than declare scientific truth.
Regulation Is Moving Toward Model Credibility
As AI-generated evidence becomes more involved in drug development, regulators are paying closer attention to how models are designed, validated, and used.
Important principles include:
- An AI model should have a clearly defined context of use.
- Its data sources and limitations should be documented.
- Performance should be evaluated using appropriate evidence.
- Higher-risk applications require stronger validation.
- AI-generated evidence should remain traceable and reviewable.
The most valuable biological AI systems will therefore not be those that produce the largest number of predictions. They will be systems that generate reproducible, explainable, and experimentally testable results.
The PeachBot Computational Biology Perspective
PeachBot's research direction focuses on in-silico biological modelling, algorithmic analysis, and responsible computational workflows rather than wet-laboratory experimentation.
Within this framework, AI can support:
- Biological network analysis
- Protein interaction modelling
- Computational hypothesis generation
- Genomic and proteomic data interpretation
- Simulation-driven research
- Reproducible biological data pipelines
- Edge-based processing of sensitive research datasets
Learn more about AI and Computational Biology research at PeachBot.
A responsible computational biology platform should preserve the separation between prediction and evidence. Models can identify patterns and generate hypotheses, while qualified researchers and regulated institutions remain responsible for laboratory validation, clinical investigation, and medical decisions.
Why Edge and Local AI Infrastructure Matter
Biological and healthcare datasets can be sensitive, large, and difficult to transfer securely.
Local or edge-based AI infrastructure may help research teams:
- Process sensitive datasets closer to their source
- Reduce unnecessary transfer of raw biological data
- Operate in environments with limited internet connectivity
- Maintain greater control over model execution
- Build auditable and reproducible computational workflows
- Reduce dependence on continuous public-cloud access
This is especially relevant for hospitals, laboratories, universities, and research institutions working with confidential genomic, clinical, or molecular information.
The Future of AI Drug Discovery
The next stage of AI drug discovery will probably be shaped by the convergence of several technologies:
- Biological foundation models that process multiple molecular types
- Multi-omics systems connecting genes, proteins, and cellular behaviour
- AI agents coordinating complex computational workflows
- Automated laboratories testing model-generated hypotheses
- Open research models increasing access to advanced biological AI
- Privacy-preserving infrastructure for sensitive biological data
- Human-supervised systems with reproducible scientific audit trails
The largest breakthrough may not come from one model generating a perfect drug. It may come from creating a reliable learning loop in which computational predictions, laboratory evidence, and human scientific judgement continuously improve one another.
Conclusion
AI drug discovery is moving from isolated prediction tools toward integrated biological reasoning systems.
The most important development is the emergence of biological foundation models and lab-in-the-loop platforms capable of connecting molecular modelling with experimental feedback. These technologies may help scientists explore more candidates, design better experiments, and identify promising therapeutic hypotheses faster.
However, AI predictions are only the beginning of the scientific process. Laboratory evidence, clinical validation, regulatory review, transparency, and human oversight remain essential.
The future of AI in healthcare will depend not merely on generating more biological predictions, but on converting computational intelligence into credible, reproducible, and responsibly validated scientific knowledge.
Frequently Asked Questions
What is AI drug discovery?
AI drug discovery is the use of machine learning, deep learning, and computational modelling to analyse biological information, identify therapeutic targets, screen compounds, and generate potential drug candidates.
Can AI create a new medicine?
AI can generate or prioritise potential molecules, but it cannot independently establish that a molecule is a safe and effective medicine. Laboratory testing, preclinical studies, clinical trials, and regulatory approval are still required.
How is computational biology used in drug discovery?
Computational biology helps researchers analyse genes, proteins, molecular interactions, and biological networks. These analyses can support target identification, biomarker discovery, drug repurposing, and candidate prioritisation.
What is lab-in-the-loop AI?
Lab-in-the-loop AI is a research workflow in which AI generates predictions, laboratory experiments test those predictions, and the experimental results are returned to the AI system for further improvement.
Will AI replace pharmaceutical researchers?
AI is more likely to augment pharmaceutical researchers by accelerating data analysis and experimental planning. Scientific judgement, laboratory expertise, clinical evaluation, and regulatory oversight remain necessary.
Is an AI-predicted drug ready for patient use?
No. An AI-predicted molecule remains a research candidate until it has completed the required laboratory, preclinical, clinical, and regulatory processes.
